跳到正文
原文
MedPage Today·· 15 小时前精选AI 评分79

FDA批准venglustat为首个治疗3型戈谢病神经系统症状的药物

FDA Approves First Treatment for Neurologic Symptoms of Type 3 Gaucher Disease

AI 导读

FDA已批准口服venglustat(Infilbray)片剂作为首个治疗成人和体重≥15kg儿童3型戈谢病患者神经系统症状的药物。该批准基于LEAP2MONO III期临床试验结果,52周时venglustat在共济失调和认知功能方面较酶替代治疗imiglucerase展现出显著改善(P=0.0137)。说明书含黑框警告,提示自杀意念与行为风险、儿童晶状体混浊及妊娠期胚胎胎儿毒性。

推荐理由

原文明确给出FDA批准事项与适用人群,读者可据此判断对3型戈谢病患者及同类产品的临床路径影响。

正文

— Oral venglustat led to improvements in symptoms related to ataxia and cognitive function

by Judy George, Deputy Managing Editor, MedPage Today

November 19, 2026 • 2 min read

The FDA approved venglustat (Infilbray) tablets as the first treatment for neurologic symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, the agency announced Wednesday.

Gaucher disease is a rare, inherited lysosomal storage disorder caused by a deficiency of glucocerebrosidase. Without this enzyme, glycosphingolipids build up, mainly in macrophages in the spleen, liver, bone marrow, and lungs. In type 3 Gaucher disease, these lipids also accumulate in the central nervous system and lead to neurologic symptoms including cognitive deficits or problems with coordination and balance.

Venglustat is a novel oral glucosylceramide synthase inhibitor designed to cross the blood-brain barrier. By limiting abnormal glycosphingolipid buildup and its effects, it may help slow the progression of type 3 Gaucher disease.

"We have been able to treat the systemic manifestations of type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies," Pramod Mistry, MD, PhD, of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center in New Haven, Connecticut, said in a news release. "The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global type 3 Gaucher disease community."

The FDA's decision was based on data from the phase III LEAP2MONO trial, which compared daily oral venglustat versus intravenous infusions of the enzyme replacement therapy imiglucerase (Cerezyme) in 43 patients ages 12 and older. Study participants had previously achieved stabilization of their systemic manifestations with enzyme replacement therapy. At 52 weeks, a global test of multiple neurologic endpoints showed that venglustat achieved significant improvements in symptoms related to ataxia and cognitive function (P=0.0137).

The most frequently reported side effects with venglustat included gastrointestinal symptoms and adverse effects on mood, the FDA said. "Serious psychiatric risks, including suicidal ideation and behavior, have been reported," the agency pointed out. "Potential risks identified from animal studies include potential clouding of vision in younger patients and adverse effects on fetal development when drug is taken during pregnancy."

Prescribing information includes warnings and precautions for suicidal ideation and behavior, lens opacification in pediatric patients, and embryo-fetal toxicity.

The open-label phase of the LEAP2MONO study is ongoing and results will be presented when available, drugmaker Sanofi said.

来源:MedPage Today · medpagetoday.com